TNF-inhibitors (adalimumab) and Drug-induced lupus: is the FAERS signal real?
TNF-inhibitors (adalimumab) ↔ Drug-induced lupus
Reporting over time (stimulated-reporting check)
Reporting spiked in 2024, 2025 — 27% of all 2,338 reports arrived in two years (2024–2025). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
TNF-alpha inhibitors (adalimumab, infliximab, etanercept) are well documented in the rheumatology literature to induce a lupus-like syndrome, with clinically evident cases in roughly 0.2% of treated patients across the class — strikingly close to this dataset's own trial-derived rate for adalimumab specifically (see the trial box below). Published reviews put infliximab and etanercept ahead of adalimumab in how often they trigger antinuclear/anti-dsDNA antibody formation, so adalimumab is, if anything, a conservative example of a class-wide effect rather than its worst case. Onset is typically around 11 months into therapy (joint and skin manifestations predominate: malar/annular rash, arthralgia, sometimes myositis), and symptoms resolve over three weeks to six months after the drug is stopped — a real dechallenge pattern, not instant, but documented. This is a recognized, labeled class effect, not specific to adalimumab.
Regulatory basis: TNF-inhibitor class labeling (autoimmunity/lupus-like reactions warning). Anti-TNF-α-induced lupus, review: PMC6852950.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Typically emerges after months of therapy |
| Strength | partial | PRR 18.4, moderate |
| Consistency | met | Replicated class-wide (adalimumab, infliximab, etanercept) |
| Specificity | partial | Class effect |
| Biological gradient | not established | No clear dose-response demonstrated |
| Plausibility | met | Anti-dsDNA / anti-histone antibody induction is documented |
| Coherence | met | Fits known TNF-inhibitor immunology |
| Experiment | met | Symptoms resolve after stopping the drug (dechallenge) — the most direct evidence on this page short of a trial |
| Analogy | met | Classic "drug-induced lupus" category shared with older drugs (hydralazine, procainamide) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — long-term Humira registry (NCT00524537), N=5,025
| Event | Adalimumab (n=5,025) |
|---|---|
| Lupus-like syndrome (any) | 11 (0.22%) |
| Systemic lupus erythematosus | 9 (0.18%) |
| Cutaneous lupus erythematosus | 1 (0.02%) |
A single-arm long-term registry (no placebo comparator), but with a real denominator across 5,025 patients — direct evidence the event genuinely occurs at a low but non-zero, quantifiable rate under real-world adalimumab use, independent of FAERS's passive-report counting. View on ClinicalTrials.gov →